Welcome to our dedicated page for ASLAN Pharmaceuticals American Depositary Shares news (Ticker: ASLN), a resource for investors and traders seeking the latest updates and insights on ASLAN Pharmaceuticals American Depositary Shares stock.
ASLAN Pharmaceuticals Limited (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company dedicated to developing innovative treatments that transform the lives of patients. Headquartered in Singapore with offices in Taiwan and China, ASLAN is tackling high-prevalence diseases in Asia and orphan indications in the United States and Europe.
ASLAN's strategic portfolio includes four product candidates targeting validated growth pathways, novel immune checkpoints, and cancer metabolic pathways. Their flagship projects are eblasakimab, a first-in-class antibody targeting the IL-13 receptor for moderate-to-severe atopic dermatitis (AD), and farudodstat, an oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) for alopecia areata (AA).
In recent developments, eblasakimab has shown promising results in a Phase 2b, dose-ranging study, achieving significant improvements in AD patients. Concurrently, farudodstat is progressing through a Phase 2a, proof-of-concept trial with interim results expected soon.
ASLAN actively collaborates with industry leaders such as Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL to bolster their research and development efforts. The company's strategic alliances aim to leverage combined expertise for enhanced therapeutic outcomes.
On March 12, 2024, ASLAN announced a definitive agreement to sell 5,000,000 American Depositary Shares (ADSs) at $1.00 per ADS in a direct offering, with warrants issued in a concurrent private placement. The proceeds will fund ongoing R&D activities and general corporate purposes.
Despite financial challenges, including a reported deficit of $13.3 million in stockholders’ equity for 2023, ASLAN is committed to regaining compliance with Nasdaq listing requirements. This determination is underscored by their continuous efforts to advance their clinical pipeline and explore new research collaborations, such as their recent agreement with Zenyaku Kogyo Co., Ltd.
ASLAN's proactive approach, supported by a solid management team with deep global and regional expertise, aims to generate significant clinical advances and commercial opportunities. For more information, visit the ASLAN website or follow them on LinkedIn.
ASLAN Pharmaceuticals (Nasdaq: ASLN), a biopharmaceutical company focused on immunology, announces participation in the Jefferies London Healthcare Conference from November 15 to 17, 2022. CEO Dr. Carl Firth and CBO Mr. Stephen Doyle will meet with investors at the Waldorf Hilton hotel in London. ASLAN is developing innovative treatments including eblasakimab for atopic dermatitis and farudodstat for autoimmune diseases. For more details, visit www.aslanpharma.com.
ASLAN Pharmaceuticals (ASLN) reported Q3 2022 financial results, noting a net loss of $10.9 million compared to a loss of $8.6 million in Q3 2021. The company maintains a strong cash position of $68.9 million, ensuring operational runway through late 2023. Key clinical developments include the TREK-AD and TREK-DX trials for eblasakimab in atopic dermatitis, with topline data expected in Q2 2023. The firm also presented promising data on eblasakimab's efficacy at the EADV congress, positioning it as a potential preferred treatment for moderate-to-severe AD.
ASLAN Pharmaceuticals (NASDAQ: ASLN) presented new data at the 51st Annual European Society for Dermatological Research Meeting, focusing on eblasakimab's role in atopic dermatitis (AD). Collaborative research showed heightened IL-13Rα1 expression in mast cells and eosinophils from AD patients, underscoring its significance in AD pathology. Eblasakimab notably reduced neuronal itch sensitization linked to IL-4 and IL-13 pathways. The data suggest that eblasakimab could provide a unique therapeutic approach targeting IL-13Rα1 to improve outcomes for AD patients.
ASLAN Pharmaceuticals (Nasdaq: ASLN) has announced plans to initiate the TREK-DX trial in Q4 2022, evaluating eblasakimab for moderate-to-severe atopic dermatitis (AD) in patients previously treated with dupilumab. This trial complements the existing TREK-AD study for biologic-naïve patients. The TREK-DX trial will enroll 75 patients and assess the drug's efficacy and safety. ASLAN confirms this initiative will not affect its cash runway. The results could position eblasakimab as a first-choice treatment for AD.
ASLAN Pharmaceuticals (NASDAQ: ASLN) has announced acceptance of two late-breaking e-posters on eblasakimab at the 51st Annual European Society for Dermatological Research Meeting, scheduled from September 28 to October 1, 2022, in Amsterdam. The posters focus on new translational data regarding IL-13Rα1 signaling in atopic dermatitis. Eblasakimab is a potential first-in-class monoclonal antibody aimed at treating moderate-to-severe atopic dermatitis. The posters will be accessible online after their presentation.
ASLAN Pharmaceuticals (NASDAQ: ASLN) presented new data on eblasakimab at the 2022 EADV congress, revealing its effectiveness in treating moderate-to-severe atopic dermatitis. The findings indicate that eblasakimab significantly reduces inflammatory biomarkers, itch, and sleep disturbances, with effects lasting 4-6 weeks post-treatment. In an 8-week study, patients receiving the 600 mg dose showed a 48% improvement in itch and notable sleep quality enhancements. This data supports ongoing Phase 2b trials for eblasakimab, positioning it as a potential first-in-class therapy for atopic dermatitis.
ASLAN Pharmaceuticals (Nasdaq:ASLN) announced that CEO Dr. Carl Firth will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 10:30 am ET. The conference is set to occur from September 12 to 14, 2022, at the Lotte New York Palace Hotel, with both in-person and virtual attendance options. An on-demand recording of the presentation will be available on ASLAN’s Investor Relations website starting September 12. Management will also hold one-on-one meetings with investors during the conference.
ASLAN Pharmaceuticals (Nasdaq: ASLN) has licensed Belle.ai's belleStudy™ digital image capture software to enhance its ongoing phase 2b clinical trial of eblasakimab for atopic dermatitis (AD). The software will be used by trial investigators to standardize and improve the quality of disease severity assessments through AI-guided image capture. Topline data from the TREK-AD trial is expected in early 2023, highlighting ASLAN's commitment to innovative solutions in clinical trials and patient management.
ASLAN Pharmaceuticals (Nasdaq: ASLN) will host an R&D Day on September 15, 2022, from 10:00 AM to 1:30 PM ET in New York City. Key Opinion Leaders in dermatology will discuss unmet needs and the therapeutic landscape for moderate-to-severe atopic dermatitis (AD). The event will provide updates on the pipeline, particularly eblasakimab, a novel monoclonal antibody targeting the IL-13 receptor α1 subunit. Presentations will cover translational data, clinical results, and the development strategy for eblasakimab. Registration for in-person and virtual attendance is available on ASLAN's website.
ASLAN Pharmaceuticals (ASLN) reported a net loss of $13.0 million for Q2 2022, up from $5.4 million in Q2 2021. As of June 30, 2022, the company had $78.1 million in cash and equivalents, providing a financial runway until late 2023. Eblasakimab's Phase 2b TREK-AD trial remains on schedule for topline data in H1 2023. The company has also accepted three abstracts for presentation at the EADV Annual Congress in September 2022. R&D expenses soared to $10.0 million in Q2 2022, increasing year-over-year due to trial costs.
FAQ
What is the current stock price of ASLAN Pharmaceuticals American Depositary Shares (ASLN)?
What is the market cap of ASLAN Pharmaceuticals American Depositary Shares (ASLN)?
What is ASLAN Pharmaceuticals' focus?
What are ASLAN Pharmaceuticals' main products?
Where is ASLAN Pharmaceuticals headquartered?
Who are ASLAN Pharmaceuticals’ partners?
What recent financial activities has ASLAN Pharmaceuticals undertaken?
What clinical advancements has ASLAN Pharmaceuticals made recently?
How is ASLAN Pharmaceuticals addressing its financial challenges?
What is the purpose of ASLAN Pharmaceuticals’ recent collaboration with Zenyaku Kogyo?
What is eblasakimab?
What are the potential benefits of farudodstat?
